Dr. Julie Decock received her Master of Science (MSc) in Biomedical Sciences from the Free University of Brussels (VUB, Belgium) and completed her Doctor of Philosophy (PhD) in Medical Sciences at the Catholic University of Leuven, KULeuven, Belgium.
During her PhD she co-founded the breast cancer biobank at the University Hospital of Leuven, Belgium.
She joined Qatar Biomedical Research Institute (QBRI), in 2013 as a postdoctoral researcher and established the cancer-immune ecosystem group in 2016. In addition, she holds an assistant professor position at HBKU’s College of Health and Life Sciences (CHLS).
Qatar Biomedical Research Institute (QBRI), Qatar.2016 - present
College of Health and Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Doha, Qatar.2016 - present
Cancer Research Center, Qatar Biomedical Research Institute (QBRI), Qatar.2013 - 2016
School of Biological Sciences, Faculty of Science, University of East Anglia (UEA), UK.2008 - 2013
Faculty of Medicine, Catholic University of Leuven (KULeuven), Belgium2008
Free University of Brussels (VUB), Belgium2002
Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab and European ancestry. Npj Breast Cancer, in press.
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors. Front. Oncol., doi:10.3389/fonc.2020.598626.2020
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy. Cancer Immunol Immunother. 2020 Jan 13. doi: 10.1007/s00262-020-02480-4.2020
The obesity paradox in cancer, tumor immunology and immunotherapy: Focus on triple negative breast cancer. Front. Immunol. 10:1940. doi: 10.3389/fimmu.2019.01940. Review.2019
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Cancers (Basel). 2019 Jul 15; 11(7). Review.2019
PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med. 17(1):9. doi: 10.1186/s12967-018-1757-3.2019
NY-ESO-1 based immunotherapy of cancer: current perspectives. Front. Immunol. 9:947. doi: 10.3389/fimmu.2018.00947. Review.2018